Compare ZLAB & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZLAB | TMDX |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 2017 | 2019 |
| Metric | ZLAB | TMDX |
|---|---|---|
| Price | $22.62 | $76.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 13 |
| Target Price | $33.14 | ★ $99.82 |
| AVG Volume (30 Days) | ★ 712.3K | 702.1K |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.46 | ★ 382.18 |
| EPS | N/A | ★ 0.61 |
| Revenue | $460,156,000.00 | ★ $605,494,000.00 |
| Revenue This Year | N/A | $22.57 |
| Revenue Next Year | $26.50 | $17.85 |
| P/E Ratio | ★ N/A | $129.73 |
| Revenue Growth | 15.33 | ★ 37.13 |
| 52 Week Low | $15.96 | $60.11 |
| 52 Week High | $30.00 | $156.00 |
| Indicator | ZLAB | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 34.34 | 36.46 |
| Support Level | $16.97 | $66.64 |
| Resistance Level | $27.14 | $79.60 |
| Average True Range (ATR) | 1.03 | 3.56 |
| MACD | -0.36 | -0.60 |
| Stochastic Oscillator | 9.48 | 8.84 |
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.